Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Cantor Fitzgerald

Astria Therapeutics (NASDAQ:ATXS) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on ATXS. Wedbush reiterated an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective on the stock. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $30.00.

Astria Therapeutics Trading Up 3.2 %

Shares of NASDAQ ATXS opened at $5.12 on Tuesday. The stock has a market capitalization of $288.94 million, a PE ratio of -2.45 and a beta of 0.68. The stock has a fifty day simple moving average of $5.48 and a 200-day simple moving average of $8.01. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.01. On average, equities analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its stake in shares of Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 7,971 shares during the last quarter. California State Teachers Retirement System raised its position in Astria Therapeutics by 9.9% during the 4th quarter. California State Teachers Retirement System now owns 32,561 shares of the biotechnology company’s stock worth $291,000 after buying an additional 2,935 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Astria Therapeutics by 13.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company’s stock worth $567,000 after acquiring an additional 7,756 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after acquiring an additional 180,000 shares in the last quarter. Finally, Sphera Funds Management LTD. increased its stake in shares of Astria Therapeutics by 2.4% during the fourth quarter. Sphera Funds Management LTD. now owns 139,800 shares of the biotechnology company’s stock worth $1,250,000 after acquiring an additional 3,218 shares during the period. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.